Mepolizumab (Nucala) helped prevent exacerbations of chronic obstructive pulmonary disease (COPD) when added to background ...

Chronic obstructive pulmonary disease ... also considers your individual symptoms and history of acute exacerbations. As the disease progresses, you’re more susceptible to complications ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

More people may be at risk for developing COPD due to exposure to environmental irritants, such as heat waves and air ...

A new study published in the journal of BMC Pulmonary Medicine showed that dyspnea (mMRC score 1.67), symptom load (CAT score ...

The relationship between chronic obstructive pulmonary disease (COPD ... including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly patient.

Virtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets ... reduced the number of annual exacerbations by as much as 30%, and improved lung function (forced expiratory ...

Chronic obstructive pulmonary disease (COPD), an irreversible form ... plan can help you control your COPD symptoms and avoid exacerbations (flareups). These include shortness of breath, wheezing ...